Research ExplorerPublicationsHEV infection in stem cell transplant recipients-retrospecti...

HEV infection in stem cell transplant recipients-retrospective study of EBMT Infectious Diseases Working Party

Standard

HEV infection in stem cell transplant recipients-retrospective study of EBMT Infectious Diseases Working Party. / Mikulska, Malgorzata; Penack, Olaf; Wendel, Lotus; Knelange, Nina; Cornelissen, Jan J; Blijlevens, Nicole; Passweg, Jakob R; Kroger, Nicolaus; Bruns, Anke; Koenecke, Christian; Bierings, Marc; Piñana, José Luis; Labussiere-Wallet, Helene; Ghesquieres, Herve; Diaz, Miguel Angel; Sampol, Antonia; Averbuch, Diana; de la Camara, Rafael; Styczynski, Jan.

In: BONE MARROW TRANSPL, Vol. 57, No. 2, 02.2022, p. 167-175.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Mikulska, M, Penack, O, Wendel, L, Knelange, N, Cornelissen, JJ, Blijlevens, N, Passweg, JR, Kroger, N, Bruns, A, Koenecke, C, Bierings, M, Piñana, JL, Labussiere-Wallet, H, Ghesquieres, H, Diaz, MA, Sampol, A, Averbuch, D, de la Camara, R & Styczynski, J 2022, 'HEV infection in stem cell transplant recipients-retrospective study of EBMT Infectious Diseases Working Party', BONE MARROW TRANSPL, vol. 57, no. 2, pp. 167-175. https://doi.org/10.1038/s41409-021-01497-2

APA

Mikulska, M., Penack, O., Wendel, L., Knelange, N., Cornelissen, J. J., Blijlevens, N., Passweg, J. R., Kroger, N., Bruns, A., Koenecke, C., Bierings, M., Piñana, J. L., Labussiere-Wallet, H., Ghesquieres, H., Diaz, M. A., Sampol, A., Averbuch, D., de la Camara, R., & Styczynski, J. (2022). HEV infection in stem cell transplant recipients-retrospective study of EBMT Infectious Diseases Working Party. BONE MARROW TRANSPL, 57(2), 167-175. https://doi.org/10.1038/s41409-021-01497-2

Vancouver

Mikulska M, Penack O, Wendel L, Knelange N, Cornelissen JJ, Blijlevens N et al. HEV infection in stem cell transplant recipients-retrospective study of EBMT Infectious Diseases Working Party. BONE MARROW TRANSPL. 2022 Feb;57(2):167-175. https://doi.org/10.1038/s41409-021-01497-2

Bibtex

@article{5e2f46a124654167b1db0c0a46202e06,
title = "HEV infection in stem cell transplant recipients-retrospective study of EBMT Infectious Diseases Working Party",
abstract = "HEV infection is an emerging cause of acute and chronic hepatitis in stem cell transplant (SCT) recipients. We performed a retrospective observational study among EBMT centers with the aim of describing characteristics, management and outcome of HEV after SCT. There were 34 cases of HEV infection from 12 centers in 6 countries, diagnosed in median 4.5 months after SCT; 20 of acute and 14 of chronic infection. Non-hepatic findings possibly associated with HEV infection were present in 9 (26%). Patients with chronic infection had more characteristics associated with severely immunocompromised status. Ribavirin was provided to 16 patients (47%; 40% with acute and 57% with chronic infection), in median for 75 days. Three (19%) patients discontinued it due to side effects. HEV-RNA clearance occurred in 29 patients (85%; 85% in acute and 86% in chronic infection). HEV was considered a cause of death in 3 (9%), with 2 cases with late diagnosis. Reduction of immunosuppression in those receiving it, and ribavirin treatment in those with chronic infection were associated with shorter time to HEV-RNA clearance. Policy on HEV testing varied between the centers. In conclusion, acute and chronic HEV hepatitis should be promptly diagnosed and managed in SCT recipients.",
author = "Malgorzata Mikulska and Olaf Penack and Lotus Wendel and Nina Knelange and Cornelissen, {Jan J} and Nicole Blijlevens and Passweg, {Jakob R} and Nicolaus Kroger and Anke Bruns and Christian Koenecke and Marc Bierings and Pi{\~n}ana, {Jos{\'e} Luis} and Helene Labussiere-Wallet and Herve Ghesquieres and Diaz, {Miguel Angel} and Antonia Sampol and Diana Averbuch and {de la Camara}, Rafael and Jan Styczynski",
note = "{\textcopyright} 2021. The Author(s), under exclusive licence to Springer Nature Limited.",
year = "2022",
month = feb,
doi = "10.1038/s41409-021-01497-2",
language = "English",
volume = "57",
pages = "167--175",
journal = "BONE MARROW TRANSPL",
issn = "0268-3369",
publisher = "NATURE PUBLISHING GROUP",
number = "2",

}

RIS

TY - JOUR

T1 - HEV infection in stem cell transplant recipients-retrospective study of EBMT Infectious Diseases Working Party

AU - Mikulska, Malgorzata

AU - Penack, Olaf

AU - Wendel, Lotus

AU - Knelange, Nina

AU - Cornelissen, Jan J

AU - Blijlevens, Nicole

AU - Passweg, Jakob R

AU - Kroger, Nicolaus

AU - Bruns, Anke

AU - Koenecke, Christian

AU - Bierings, Marc

AU - Piñana, José Luis

AU - Labussiere-Wallet, Helene

AU - Ghesquieres, Herve

AU - Diaz, Miguel Angel

AU - Sampol, Antonia

AU - Averbuch, Diana

AU - de la Camara, Rafael

AU - Styczynski, Jan

N1 - © 2021. The Author(s), under exclusive licence to Springer Nature Limited.

PY - 2022/2

Y1 - 2022/2

N2 - HEV infection is an emerging cause of acute and chronic hepatitis in stem cell transplant (SCT) recipients. We performed a retrospective observational study among EBMT centers with the aim of describing characteristics, management and outcome of HEV after SCT. There were 34 cases of HEV infection from 12 centers in 6 countries, diagnosed in median 4.5 months after SCT; 20 of acute and 14 of chronic infection. Non-hepatic findings possibly associated with HEV infection were present in 9 (26%). Patients with chronic infection had more characteristics associated with severely immunocompromised status. Ribavirin was provided to 16 patients (47%; 40% with acute and 57% with chronic infection), in median for 75 days. Three (19%) patients discontinued it due to side effects. HEV-RNA clearance occurred in 29 patients (85%; 85% in acute and 86% in chronic infection). HEV was considered a cause of death in 3 (9%), with 2 cases with late diagnosis. Reduction of immunosuppression in those receiving it, and ribavirin treatment in those with chronic infection were associated with shorter time to HEV-RNA clearance. Policy on HEV testing varied between the centers. In conclusion, acute and chronic HEV hepatitis should be promptly diagnosed and managed in SCT recipients.

AB - HEV infection is an emerging cause of acute and chronic hepatitis in stem cell transplant (SCT) recipients. We performed a retrospective observational study among EBMT centers with the aim of describing characteristics, management and outcome of HEV after SCT. There were 34 cases of HEV infection from 12 centers in 6 countries, diagnosed in median 4.5 months after SCT; 20 of acute and 14 of chronic infection. Non-hepatic findings possibly associated with HEV infection were present in 9 (26%). Patients with chronic infection had more characteristics associated with severely immunocompromised status. Ribavirin was provided to 16 patients (47%; 40% with acute and 57% with chronic infection), in median for 75 days. Three (19%) patients discontinued it due to side effects. HEV-RNA clearance occurred in 29 patients (85%; 85% in acute and 86% in chronic infection). HEV was considered a cause of death in 3 (9%), with 2 cases with late diagnosis. Reduction of immunosuppression in those receiving it, and ribavirin treatment in those with chronic infection were associated with shorter time to HEV-RNA clearance. Policy on HEV testing varied between the centers. In conclusion, acute and chronic HEV hepatitis should be promptly diagnosed and managed in SCT recipients.

U2 - 10.1038/s41409-021-01497-2

DO - 10.1038/s41409-021-01497-2

M3 - SCORING: Journal article

C2 - 34689177

VL - 57

SP - 167

EP - 175

JO - BONE MARROW TRANSPL

JF - BONE MARROW TRANSPL

SN - 0268-3369

IS - 2

ER -